Geron (NASDAQ:GERN) stock is rocketing higher on Friday following news that advisors to the Food and Drug Administration (FDA) are backing its blood disorder drug, imetelstat.According to a press release from late-stage clinical biopharmaceutical company, the Oncologic Drugs Advisory Committee (ODAC) voted 12 to two in favor of imetelstat. The ODAC specifically noted that the benefits of the drug outweigh the risks.The ODAC reached its conclusion on imetelstat after reviewing data from a Phase 3 clinical tr ...

Geron Corporation (GERN) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) voted in favor of the clinical benefit/risk profile of pipeline candidate, imetelstat, for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs).The ODAC voted 12:2 in favor of imetelstat’s benefits over risks.Consequently, sh ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 ...

ktsimage Investment Overview I last updated on Geron Corporation (NASDAQ:GERN), the Foster City, California-based biotech primarily focused on securing commercial approval in the U.S. for its lead candidate, imetelstat, in the indication of transfusion-dependent anemia in adult patients, with low-to-intermediate-1 risk myelodysplastic syndromes ("MDS"), in a note for Seeking Alpha back in early December last year. I gave the company and its stock a "Buy" rating, based on my belief that the FDA is likely to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-20859 For the transition period from to . GERON CORPORATION (Exact name of registrant as specified in its charter) | Delaware | | 75-2287752 | | --- | --- | --- | | ( ...

Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript February 28, 2024 8:00 AM ET Company Participants Aron Feingold - VP of IR and Corporate Communications John Scarlett - Chairman and CEO Faye Feller - EVP and CMO Anil Kapur - EVP of Corporate Strategy and CCO Michelle Robertson - EVP and CFO Conference Call Participants Corinne Johnson - Goldman Sachs Kalpit Patel - B. Riley Stephen Willey - Stifel Ethan Markowski - Needham & Company Joel Beatty - Baird Operator Good morning. My name is Rob a ...

*Mutation data were available for 18/21 patients receiving imetelstat with ≥1-year TI LR-MDS: lower-risk myelodysplastic syndromes; TI: transfusion independence; VAF: variant allele frequency Conclusion • With a median TI duration over 2 years, • Elimination of MDSassociated mutations suggests the potential of imetelstat to have disease-modifying activity. ASH 2023: Durable TI Associated with Better Survival Abstract #2440 Conclusion For transfusion dependent patients achievement of TI with second line trea ...

Geron Corporation (NASDAQ:GERN) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Corporate Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications John Scarlett - Chairman, President and Chief Executive Officer Faye Feller - Executive Vice President and Chief Medical Officer Anil Kapur - Executive Vice President, Corporate Strategy and Chief Commercial Officer Michelle Robertson - Executive Vice President and Chief Financial Officer Conference Call Participan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 75-2287752 (State or other jurisdi ...

Geron Corporation (NASDAQ:GERN) Q2 2023 Results Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications John Scarlett - Chairman of the Board, President and Chief Executive Officer Faye Feller - Executive Vice President and Chief Medical Officer Anil Kapur - Executive Vice President, Corporate Strategy and Chief Commercial Officer Olivia Bloom - Executive Vice President, Finance, Chief Financial Officer and Treas ...